Royal Bank Of Canada Reiterates Buy Rating for Johnson & Johnson (JNJ)
Royal Bank Of Canada reaffirmed their buy rating on shares of Johnson & Johnson (NYSE:JNJ) in a research report report published on Wednesday morning. Royal Bank Of Canada currently has a $138.00 price target on the stock.
Several other research firms have also issued reports on JNJ. Morgan Stanley boosted their target price on Johnson & Johnson from $135.00 to $140.00 and gave the stock an overweight rating in a research report on Wednesday, July 5th. BidaskClub lowered Johnson & Johnson from a strong-buy rating to a buy rating in a research report on Saturday, July 1st. Vetr lowered Johnson & Johnson from a buy rating to a hold rating and set a $128.54 target price for the company. in a research report on Monday, May 1st. Jefferies Group LLC restated a hold rating and set a $140.00 target price on shares of Johnson & Johnson in a research report on Friday, June 16th. Finally, BTIG Research restated a hold rating on shares of Johnson & Johnson in a research report on Wednesday, April 19th. Eleven investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $133.65.
Johnson & Johnson (NYSE JNJ) opened at 132.15 on Wednesday. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.00. The firm has a 50 day moving average of $130.42 and a 200 day moving average of $122.68. The firm has a market capitalization of $355.99 billion, a PE ratio of 22.21 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 18th. The company reported $1.83 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.77 by $0.06. The firm had revenue of $17.77 billion during the quarter, compared to analysts’ expectations of $18.02 billion. Johnson & Johnson had a return on equity of 26.50% and a net margin of 22.87%. The company’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same period in the previous year, the business posted $1.68 EPS. Equities analysts forecast that Johnson & Johnson will post $7.10 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be given a $0.84 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 annualized dividend and a dividend yield of 2.54%. Johnson & Johnson’s dividend payout ratio is presently 56.47%.
A number of institutional investors have recently added to or reduced their stakes in the company. CWM LLC increased its position in Johnson & Johnson by 1.3% in the second quarter. CWM LLC now owns 15,593 shares of the company’s stock worth $2,063,000 after buying an additional 195 shares during the period. Canal Capital Management LLC increased its position in Johnson & Johnson by 6.9% in the second quarter. Canal Capital Management LLC now owns 15,835 shares of the company’s stock worth $2,095,000 after buying an additional 1,020 shares during the period. TNB Financial increased its position in Johnson & Johnson by 14.0% in the second quarter. TNB Financial now owns 31,472 shares of the company’s stock worth $4,163,000 after buying an additional 3,873 shares during the period. Advisors Capital Management LLC increased its position in Johnson & Johnson by 6.8% in the second quarter. Advisors Capital Management LLC now owns 76,701 shares of the company’s stock worth $10,147,000 after buying an additional 4,891 shares during the period. Finally, Windward Capital Management Co. CA increased its position in Johnson & Johnson by 2.4% in the second quarter. Windward Capital Management Co. CA now owns 90,750 shares of the company’s stock worth $12,005,000 after buying an additional 2,153 shares during the period. 66.02% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.